Skip to Content

Results of OlympiA are practice changing in treatment of breast cancer

Adjuvant olaparib treatment significantly improves invasive disease-free survival in women with BRCA mutation and high-risk HER2-negative breast cancer. With a median follow-up of 2.5 years, olaparib-treated patients had a 42% reduction in the risk of developing invasive relapse compared to placebo.

Self Diagnosis Of Early Breast Cancer

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top